4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Passage Bio, Inc. (PASG) operates in the Biotechnology industry and is headquartered in Philadelphia, United States with about 24 employees. Its market capitalization is roughly $15 million. In the fiscal year ended 2025-12-31, PASG reported $0M in revenue and ($46M) in net income.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($43M) | ($65M) | ($103M) | ($135M) | — |
| Net Income | ($46M) | ($65M) | ($102M) | ($136M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($9M) | ($10M) | ($9M) | ($10M) | ($14M) | — |
| Net Income | ($8M) | ($13M) | ($8M) | ($9M) | ($15M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $62M | $102M | $150M | $244M | — |
| Total Liabilities | $44M | $41M | $39M | $42M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PASG viewer.
About TickerBase · Data methodology & sources